ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
17.924,69
0,11%
S&P 500
5.064,20
0,91%
Dow Jones
38.225,66
0,85%
Euro vs US Dollar
1,07323
0,02%
Bitcoin
59.157,89
0,06%
Registration Strip Icon for default Registrieren Sie sich kostenlos, um Echtzeitkurse, interaktive Charts, Live-Optionsfluss und mehr zu erhalten.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Tarsus Pharmaceuticals Inc (TARS)

  7. Tarsus Pharmaceuticals Inc (TARS) News

TARS

Tarsus Pharmaceuticals (TARS)

Tarsus Pharmaceuticals Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:TARS
DatumZeitQuelleÜberschriftSymbolFirma
01/05/202423h00GlobeNewswire Inc.Tarsus to Report First Quarter 2024 Financial Results on Wednesday, May 8, 2024NASDAQ:TARSTarsus Pharmaceuticals Inc
23/04/202414h30GlobeNewswire Inc.Tarsus Strengthens Financial Position and Refinances Existing Debt with $200 Million Non-dilutive Financing Commitment from PharmakonNASDAQ:TARSTarsus Pharmaceuticals Inc
11/03/202422h57Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:TARSTarsus Pharmaceuticals Inc
11/03/202422h45Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:TARSTarsus Pharmaceuticals Inc
11/03/202422h12Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:TARSTarsus Pharmaceuticals Inc
11/03/202422h10Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:TARSTarsus Pharmaceuticals Inc
05/03/202422h30GlobeNewswire Inc.Tarsus to Participate at Upcoming Investor ConferencesNASDAQ:TARSTarsus Pharmaceuticals Inc
05/03/202422h09Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:TARSTarsus Pharmaceuticals Inc
05/03/202414h30GlobeNewswire Inc.Tarsus Introduces “Mite Party” Campaign for XDEMVY® (lotilaner ophthalmic solution) 0.25% to Educate Consumers about Demodex BlepharitisNASDAQ:TARSTarsus Pharmaceuticals Inc
01/03/202423h26Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:TARSTarsus Pharmaceuticals Inc
01/03/202423h17Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:TARSTarsus Pharmaceuticals Inc
01/03/202406h07GlobeNewswire Inc.Tarsus Announces Pricing of $100.0 Million Public OfferingNASDAQ:TARSTarsus Pharmaceuticals Inc
29/02/202423h08Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:TARSTarsus Pharmaceuticals Inc
29/02/202422h37GlobeNewswire Inc.Tarsus Announces Proposed $100.0 Million Public OfferingNASDAQ:TARSTarsus Pharmaceuticals Inc
29/02/202422h32Edgar (US Regulatory)Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuersNASDAQ:TARSTarsus Pharmaceuticals Inc
27/02/202422h22Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:TARSTarsus Pharmaceuticals Inc
27/02/202422h02Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:TARSTarsus Pharmaceuticals Inc
27/02/202412h00GlobeNewswire Inc.Tarsus Reports Strong Fourth Quarter and Full-Year 2023 Financial Results and Recent Business AchievementsNASDAQ:TARSTarsus Pharmaceuticals Inc
22/02/202414h00GlobeNewswire Inc.Tarsus Announces Positive Topline Results from Carpo, a Phase 2a Proof-of-Concept “Tick-Kill” Trial Evaluating TP-05 (lotilaner) for the Prevention of Lyme DiseaseNASDAQ:TARSTarsus Pharmaceuticals Inc
20/02/202423h00GlobeNewswire Inc.Tarsus to Report Fourth Quarter and Full Year 2023 Financial Results on Tuesday, February 27, 2024NASDAQ:TARSTarsus Pharmaceuticals Inc
31/01/202423h00GlobeNewswire Inc.Tarsus to Participate in Fireside Chat at the Sixth Annual Guggenheim Healthcare Talks ConferenceNASDAQ:TARSTarsus Pharmaceuticals Inc
30/01/202422h31Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:TARSTarsus Pharmaceuticals Inc
22/01/202423h05Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:TARSTarsus Pharmaceuticals Inc
18/01/202422h30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:TARSTarsus Pharmaceuticals Inc
08/01/202415h00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:TARSTarsus Pharmaceuticals Inc
29/12/202323h08Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:TARSTarsus Pharmaceuticals Inc
27/12/202322h23Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:TARSTarsus Pharmaceuticals Inc
22/12/202323h30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:TARSTarsus Pharmaceuticals Inc
20/12/202322h49Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:TARSTarsus Pharmaceuticals Inc
20/12/202300h30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:TARSTarsus Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:TARS

Kürzlich von Ihnen besucht

TG
BAS
BASF
CCOM
US100
US Tech 100
NYSE
MCD
McDonalds
USOTC
BNPQY
BNP Paribas (QX)
TG
432
Arbor Metals
USOTC
RHHBY
Roche (QX)
DBI
MDAX
MDAX
NASDAQ
MSFT
Microsoft
NYSE
DIS
Walt Disney
CCOM
US30
US 30
AMEX
SPY
SPDR S&P 500
NYSE
JPM
JP Morgan Chase
TG
DTE
Deutsche Telekom
FX
EURUSD
Euro vs US Dollar
COIN
SOLUSD
Solana
TG
RHM
Rheinmetall
Delayed Upgrade Clock
ADVFN Logo

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten